Bio-Works Receives Order Worth SEK 2.4 Million from New European Customer in Vaccine Production

Bio-Works Technologies AB (publ) has received an order worth approximately SEK 2.4 million from a new European customer active in veterinary vaccine production. The product will be used in manufacturing processes with recurring delivery needs.

"We see it as a strong endorsement that a new player in vaccine production chooses Bio-Works as a supplier. This strengthens our position in the European market," says Lone Carlbom, CEO of Bio-Works Technologies AB.

The delivery concerns products used in the production process and represents a potential for long-term collaboration.

This disclosure contains information that Bio-Works Technologies AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 29-04-2025 16:04 CET.